Ablynx Starts Pre-Clinical Development of ALX-0962, an Anti-IgE Nanobody, to Treat Severe Allergic Asthma
5/7/2013 10:21:25 AM
More...
|
Ablynx Announces Warrant Exercise
4/22/2013 12:18:44 PM
More...
|
Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")
4/17/2013 10:52:22 AM
More...
|
Notice of Ablynx's Annual and Extraordinary General Meeting of Shareholders
3/26/2013 10:07:27 AM
More...
|
Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 2 May 2007 on the Publication of Major Shareholdings
3/11/2013 9:34:01 AM
More...
|
Ablynx Successfully Raises $41 Million
2/28/2013 8:59:53 AM
More...
|
Ablynx Announces 2012 Full Year Results
2/27/2013 10:36:30 AM
More...
|
Ablynx and Spirogen Ltd. Enter Into a Research Collaboration to Evaluate the Potential of Novel Toxin-Nanobody Drug Conjugates in Cancer
2/25/2013 9:57:26 AM
More...
|
Synthetic Llama Antibodies Soothe Arthritis Pain, Ablynx Reveals
2/22/2013 7:26:49 AM
More...
|
Ablynx Promoted to the Belgian Mid-Cap Index
2/21/2013 8:38:31 AM
More...
|
|